Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma
Status:
Completed
Trial end date:
2001-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver
tumor-killing substances to them without harming normal cells.
PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody therapy in
treating patients who have stage III or stage IV melanoma at high risk for recurrence
following surgery to remove the tumor.